Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Células T do receptor de antígeno quimérico B7-H3 (B7-H3CART) em glioblastoma multiforme recorrente

11 de novembro de 2026 atualizado por: Stanford University

Ensaio Clínico de Fase I de Células T do Receptor de Antígeno Quimérico B7-H3 Autólogo Distribuído Locorregionalmente (LR) (B7-H3CART) em Adultos com Glioblastoma Multiforme Recorrente (GBM)

This is an open label, non-randomized, single site Phase I study to test the manufacturing feasibility and safety of locoregional (LR) administration of B7-H3CART into the central nervous system of adult subjects with recurrent IDH wild-type GBM using a standard 3+3 dose escalation design.

Visão geral do estudo

Status

Ativo, não recrutando

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Real)

18

Estágio

  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • California
      • Palo Alto, California, Estados Unidos, 94305
        • Stanford Cancer Institute

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Histologically confirmed high grade (WHO Grade IV) glioma including but not limited to glioblastoma, gliosarcoma, glioblastoma with oligodendroglial features, glioblastoma with PNET features, tested as IDH wild-type, as per revised WHO 2021 criteria. Patients must also have evidence of tumor recurrence/progression by MRI (RANO criteria) after standard front-line therapy. b. First recurrence or progressive disease after a standard line therapy.

  • Resectable disease: Resection is being considered as part of the standard of care for the patient and it is thought that it is feasible that a majority of contrast-enhancing tumor mass/signal can be resected.

  • Patients must be between the ages of 18 and 75 years old (inclusive).

  • Karnofsky Performance score ≥ 60.

  • Use of steroids must be limited to ≤ 4 mg of decadron daily.

  • Adequate organ function at time of screening visit including:

    1. Hgb ≥ 12 g/dL (male) or ≥ 11.5 g/dL (females)
    2. ANC ≥ 1500/uL
    3. Platelets ≥ 100,000/uL
    4. Absolute lymphocyte count ≥150/uL
    5. Serum Creatinine ≤ 1.5mg/dl; Cr clearance should be ≥ 50 mL/min
    6. Serum AST and ALT ≤ 3x ULN (Grade 1)
    7. Total Bilirubin ≤ 1.5 X ULN
    8. PT or PTT ≤ 1.25 X ULN
    9. Cardiac ejection fraction ≥45% without signs of physiologically significant pericardial effusion or clinically significant ECG findings.
    10. Baseline oxygen saturation > 92% on room air
  • Subjects of child-bearing or child-fathering potential must be willing to use an effective method of contraception (hormonal or two barrier methods) while on study and for at least 4 months following the last CAR T cell infusion or as long as B7-H3CART are detectable in peripheral blood or CSF.

  • All female subjects of childbearing age must have a negative blood or urine pregnancy test.

  • Ability to understand and willingness to sign a written informed consent document.

  • Must be willing and able to comply with procedures, return visits and evaluations at Stanford Health Care while on this protocol.

  • Prior Therapy:

    • At least 6 weeks following completion of front-line radiation therapy.
    • At least 3 weeks post chemotherapy or 5 half-lives, whichever is shorter must have elapsed since any prior systemic therapy, except for systemic inhibitory/stimulatory immune checkpoint therapy, which requires 5 half-lives.
    • At least 4 weeks from bevacizumab treatment, which can be used only for radiation necrosis or pseudo-progression.
    • Prior cytotoxic chemotherapy, radiation, or other anticancer therapies including investigational agents discontinued at least 4 weeks prior to Day 1 of treatment.
    • Toxicities due to prior therapy must be stable and recovered to ≤ Grade 1 (except for clinically non-significant toxicities such as alopecia).

Exclusion Criteria:

  • Pregnant or patients who are breastfeeding.
  • Prior or concurrent treatment with Avastin (bevacizumab) for the purposes of recurrent disease. Avastin (bevacizumab) may have been used for radiation necrosis.
  • Prior exposure to chimeric antigen receptor (CAR) based therapies.
  • Known sensitivity or allergy to any agents/reagents used in this study.
  • Requires current anticoagulation therapy that cannot be safely paused for surgical resection and Ommaya access.
  • Prior malignancy except previously diagnosed and definitively treated more than 3 years prior to trial or whose prognosis is deemed good enough to not warrant surveillance.
  • Clinical evidence of significant increased intracranial pressure (i.e. impending herniation) or uncontrolled seizures.
  • Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management. Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment.
  • Known history of infection with HIV or hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive). A history of hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative PCR and/or nucleic acid testing.
  • Primary immunodeficiency or history of autoimmune disease (e.g. Crohn's, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years.
  • Significant medical diseases or conditions, including poorly controlled conditions: i.e. hypertension, cardiovascular disease, diabetes mellitus, chronic obstructive pulmonary disease, pulmonary fibrosis, inflammatory disorders, immunodeficiency (e.g., HIV infection), immune compromised for reasons other than malignancy (e.g., chronic corticosteroid therapy or other immunosuppressive therapy), renal failure including patients requiring dialysis, liver dysfunction, second malignancy (except treated basal cell or localized squamous cell skin carcinomas), or active infection.
  • History of bone marrow or stem cell transplantation.
  • In the investigator's judgment, the subject is unlikely to complete all protocol- required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Dose escalation

All subjects will be assigned to a dose level. Does escalation will proceed sequentially via a standard 3+3 dose escalation design in subjects who receive at least one infusion of B7-H3CART. Each dose level will include 3 to 6 subjects, starting at Dose Level 1. If Dose Level 1 is considered too toxic, the dose may be de-escalated to Dose Level -1. If Dose Level 4 is completed with no dose limiting toxicity (DLT) in six subjects, a maximum tolerated dose (MTD) may not be determined, and Dose Level 4 will instead be the maximum administered dose (MAD). T

B7-H3CART will be administered administered locoregionally (either ICV or both ICV and intratumorally (IT)) at one of the following doses:

Dose Level -1: 5 x 10^6 CAR+ cells (+/- 20%) Dose Level 1: 10 x 10^6 CAR+ cells (+/- 20%) Dose Level 2: 25 x 10^6 CAR+ cells (+/- 20%) Dose Level 3: 50 x 10^6 CAR+ cells (+/- 20%) Dose Level 4: 100 x 10^6 CAR+ cells (+/- 20%)

B7-H3CART Dose Dose Level -1 (DL-1): 5 x 106 B7-H3CART+ cells (± 20%) Dose Level 1 (DL 1): 10 x 106 B7-H3CART+ cells (± 20%) Dose Level 2 (DL2): 25 x 106 B7-H3CART+ cells (± 20%) Dose Level 3 (DL3): 50 x 106 B7-H3CART+ cells (± 20%) Dose Level 4 (DL4): 100 x 106 B7-H3CART+ cells (± 20%)

Repeated every 28 days (-7 / +14 days) as long as infusion criteria are met for a total of 6 doses, with an option for an additional 6 doses, up to a total of 12.

Outros nomes:
  • B7H3-CAR T
Experimental: Dose Expansion

After Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) is established, a total of 12 evaluable subjects (including the 6 subjects infused during the dose escalation phase) will be enrolled at the RP2D to further explore safety of repeat administrations at MTD/RP2D and conduct a preliminary assessment of benefit.

B7-H3CART will be administered administered locoregionally (either ICV or both ICV and intratumorally (IT)) at one of the following doses:

Dose Level -1: 5 x 10^6 CAR+ cells (+/- 20%) Dose Level 1: 10 x 10^6 CAR+ cells (+/- 20%) Dose Level 2: 25 x 10^6 CAR+ cells (+/- 20%) Dose Level 3: 50 x 10^6 CAR+ cells (+/- 20%) Dose Level 4: 100 x 10^6 CAR+ cells (+/- 20%)

B7-H3CART Dose Dose Level -1 (DL-1): 5 x 106 B7-H3CART+ cells (± 20%) Dose Level 1 (DL 1): 10 x 106 B7-H3CART+ cells (± 20%) Dose Level 2 (DL2): 25 x 106 B7-H3CART+ cells (± 20%) Dose Level 3 (DL3): 50 x 106 B7-H3CART+ cells (± 20%) Dose Level 4 (DL4): 100 x 106 B7-H3CART+ cells (± 20%)

Repeated every 28 days (-7 / +14 days) as long as infusion criteria are met for a total of 6 doses, with an option for an additional 6 doses, up to a total of 12.

Outros nomes:
  • B7H3-CAR T

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Number of successful manufacturing product (B7-H3CART) that met minimum assigned dose level range
Prazo: 5 years

Defined by the frequency of successful manufacturing runs of B7-H3CART that meet the established IND release criteria for the targeted dose level.

5 years
Maximum Tolerated Dose (MTD) or Recommended phase 2 dose (RP2D)
Prazo: 5 years

Defined by the frequency of subjects experiencing dose limiting toxicity (DLT) after initial infusion

5 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Porcentagem de indivíduos capazes de receber pelo menos três (3) doses de B7-H3CART
Prazo: 5 anos
5 anos
Cumulative Safety of B7-H3CART
Prazo: 5 years

At each dose level, incidence and severity of DLT, adverse events and serious adverse events after initial and subsequent infusions of LR B7-H3CART infusion. The definition of DLT in these studies uses NCI's Common Terminology Criteria for Adverse Events (CTCAEv5.0)

5 years
Immunotherapy Response Assessment in Neuro-oncology (iRANO) in subjects with recurrent IDH wild-type GBM
Prazo: 5 years

iRano response criteria will be measured by complete response, partial response, minor response, stable disease, progressive disease,

5 years
Time to progression (TTP)
Prazo: 5 years

the time from the start (surgical resection) to the date of radiographic progression (death is censored)

5 years
Median overall survival (OS)
Prazo: 5 years

time from the date of initial disease diagnosis to the date of death from any cause

5 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Reena Thomas, MD, PhD, Stanford University

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

12 de julho de 2022

Conclusão Primária (Estimado)

1 de março de 2027

Conclusão do estudo (Estimado)

1 de março de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

22 de julho de 2022

Enviado pela primeira vez que atendeu aos critérios de CQ

22 de julho de 2022

Primeira postagem (Real)

26 de julho de 2022

Atualizações de registro de estudo

Última Atualização Postada (Real)

13 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

11 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • IRB-65002
  • NCI-2022-06043 (Outro identificador: National Cancer Institute: Clinical Trials Reporting Program)

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever